Vascular Biogenics Ltd. | CIK:0001603207 | 3

  • Filed: 3/15/2018
  • Entity registrant name: Vascular Biogenics Ltd. (CIK: 0001603207)
  • Generator: Novaworks Software
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1603207/000149315218003377/0001493152-18-003377-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1603207/000149315218003377/vblt-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001603207
  • Open this page in separate window: Click
  • ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory

      g. Financial liabilities:

     

    Accounts payable

     

    Accounts payable are initially measured at fair value. In subsequent periods, the other financial liabilities are presented at amortized cost. Any difference between the consideration and the redemption value is accreted to profit or loss over the term of the liability, using the effective interest method.

     

    Financial liabilities are classified as current liabilities, unless the Company has an unconditional right to defer settlement of the liability for at least 12 months after the end of the reporting period, in which case they are classified as noncurrent liabilities.